Sahsen Ventures — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Enzymeenzyme.comin𝕏Jul 2026 · $4MAcquired
Enzyme develops a Quality Management System (QMS) software platform for life science companies including drug, biologic, device, and digital product manufacturers, designed to streamline regulatory workflows and generate FDA-ready documentation.
Enterprise SoftwareHealthtechMedical DevicesSaaSSan Francisco, US
Jared Seehafer(Founder/CEO)inJacob Graham(Founder/Vice President QA/RA)in
Co-investorsY CombinatorAg Startup Engine SeedRefactor Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.